Atezolizumab + Neoadjuvant Chemotherapy in TN Breast Cancer

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

  • Clinical Trial Information

    Trial Contact: Durand, Jennifer; Porter, Janice (Melinda)

    Trial Phone: 321.843.2026 ; 321.841.1077

  • IRB No: 17.152.11

    Protocol Abbrev: NSABP B-59

    Principal Investigator: Regan Derek Rostorfer, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: B-59/GBG 96-GeparDouze

    Treatment: Atezolizumab

    Therapies Involved: Medication; Chemotherapy ID: NCT03281954

  • Objective

    The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo.

  • Key Eligibility

    18 Years and older with Triple Negative Breast Cancer Diagnosed by Core Needle Biopsy and Confirmed on Central Testing